Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.62 |
| ▸ | ECE1 | P42892 | 12/20 | 0.61 |
| ▸ | CTSC | P53634 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052446 | 0.96 | ACE (0.59) | ACEECE1CTSCMEN1KMT2A | |
| SCHEMBL29470185 | 0.94 | ACE (0.61) | ACEECE1CTSCMEN1KMT2A | |
| SCHEMBL30052714 | 0.92 | ACE (0.64) | ACEECE1CTSCMEN1KMT2A | |
| SCHEMBL30051924 | 0.92 | ACE (0.59) | ACEECE1CTSCMEN1KMT2A | |
| SCHEMBL30052005 | 0.90 | CTSC (0.69) | ACEECE1CTSCMEN1KMT2A | |
| SCHEMBL30051511 | 0.90 | CTSC (0.64) | ACEECE1CTSCMEN1KMT2A | |
| SCHEMBL31510130 | 0.90 | ACE (0.51) | ACEECE1CTSCMEN1KMT2A | |
| SCHEMBL30051305 | 0.90 | ACE (0.72) | ACEECE1CTSCERAP2 | |
| Valyltryptophan SCHEMBL150532 | 0.90 | ACE (0.75) | ACEECE1CTSC | |
| Valyltryptophan SCHEMBL29365770 | 0.90 | ACE (0.75) | ACEECE1CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250339504-A1 | CANCER VACCINE WITH USE OF COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING RISK OF CANCER ONSET BY DETECTING CIRCULATING TUMOR CELLS | NATIONAL CANCER CENTER (JP) | 2025-11-06 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885ECE1 1629/4885CTSC 131/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ACE 486/4885ECE1 997/4885CTSC 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.